The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Celgene
Leadership - Celgene
Stock and Other Ownership Interests - Celgene
Nivolumab (nivo) + nab-paclitaxel (nab-P) + carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study.
 
David Michael Waterhouse
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly
 
Jonathan Wade Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Lilly; Trovagene; Vortex Biosciences
Research Funding - Abbvie; Array BioPharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Clovis Oncology; Corvus Pharmaceuticals; Genentech/Roche; Lilly; Threshold Pharmaceuticals
 
Ben George
Consulting or Advisory Role - Celgene; Cook Medical; Foundation Medicine; Merrimack
 
Peter J. O'Dwyer
Consulting or Advisory Role - Bristol-Myers Squibb; Five Prime Therapeutics; Forty Seven; Genentech
Research Funding - Amgen; Bayer; BBI Healthcare; Bristol-Myers Squibb; Celgene; Five Prime Therapeutics; Forty Seven; Genentech; GlaxoSmithKline; Merck; Mirati Therapeutics; Novartis; Pfizer; Pharmacyclics
 
Moncy Ye
No Relationships to Disclose
 
Tianlei Chen
Employment - Celgene
Leadership - Celgene
Stock and Other Ownership Interests - Celgene
 
Nataliya Trunova
Employment - Celgene
Leadership - Celgene
Stock and Other Ownership Interests - Celgene
 
Karen Kelly
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - ARIAD; ARIAD; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; G1 Therapeutics; Genentech/Roche; Lilly; Lilly; Synta
Research Funding - Abbvie (Inst); Celgene (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Millennium (Inst); Novartis (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Roche